Skyrizi (Risankizumab): A Targeted Therapy for Autoimmune Conditions

 Skyrizi (risankizumab-rzaa) is a prescription biologic medication approved for treating several chronic inflammatory conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and, most recently, ulcerative colitis. Developed by AbbVie, Skyrizi offers a targeted approach to managing these autoimmune diseases by modulating specific pathways in the immune system.

Mechanism of Action

Skyrizi functions by selectively binding to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By inhibiting IL-23, Skyrizi reduces inflammation associated with autoimmune conditions, leading to improvements in symptoms such as skin lesions, joint pain, and gastrointestinal discomfort. 

Approved Indications

1. Plaque Psoriasis: Skyrizi is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Clinical studies have demonstrated its efficacy in reducing skin lesions and maintaining long-term disease control.  
2. Psoriatic Arthritis: For adults with active psoriatic arthritis, Skyrizi has shown significant improvements in joint symptoms and physical function, with a favorable safety profile over extended treatment periods.  
3. Crohn’s Disease: Skyrizi is approved for treating moderately to severely active Crohn’s disease in adults. Clinical trials have reported that approximately 75% of patients experienced a clinical response at week 12 or a delayed response at week 24.  
4. Ulcerative Colitis: In June 2024, the FDA approved Skyrizi for adults with moderate to severe ulcerative colitis. Clinical trials indicated that about 20% of patients achieved remission within 12 weeks, increasing to 40% after 52 weeks of continued treatment.  

Administration and Dosage

Skyrizi is administered via subcutaneous injection. The dosing schedule typically involves an initial induction phase followed by maintenance doses every 12 weeks. Healthcare providers may administer the injections, or patients may be trained to self-inject at home, depending on individual circumstances. 

Safety and Side Effects

Skyrizi has demonstrated a favorable safety profile in clinical trials. Common side effects (≥1%) include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.  In patients with Crohn’s disease, additional side effects observed during maintenance therapy include abdominal pain, anemia, fever, back pain, and urinary tract infections. 

Serious hypersensitivity reactions, including anaphylaxis, have been reported. Skyrizi may increase the risk of infections; therefore, patients should be evaluated for tuberculosis and complete all age-appropriate vaccinations before initiating therapy. 

Considerations and Contraindications

Patients with active infections or a history of hypersensitivity to risankizumab or its excipients should not use Skyrizi. Additionally, live vaccines should be avoided during treatment due to the potential risk of infection. 

Conclusion

Skyrizi represents a significant advancement in the treatment of certain autoimmune conditions by offering targeted therapy with a favorable safety and efficacy profile. Its ability to modulate specific immune pathways provides relief for patients who may not have responded adequately to traditional treatments. As with any medication, it is essential for patients to consult with their healthcare providers to determine the most appropriate treatment strategy for their individual needs.